Meta-Analysis of Pretreatment Neutrophil-to-Lymphocyte Ratio and Survival in Breast Cancer

A 2026 meta-analysis by Ziqian Zhao synthesizing 56 studies published up to April 2026. The dataset includes pooled hazard ratios and odds ratios from 16,539 breast cancer patients to assess the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) for survival and treatment response.

Use Cases

• Evaluating the association between neutrophil-to-lymphocyte ratio and overall survival based on pooled hazard ratios.
• Assessing the relationship between pretreatment NLR and pathological complete response rates based on pooled odds ratios.
• Investigating the prognostic value of NLR for disease-free and recurrence-free survival in patients receiving neoadjuvant chemotherapy.

Strengths

• Includes data from 56 studies involving 16,539 patients.
• Reports specific pooled hazard ratios (e.g., HR=1.89 for OS) and odds ratios (OR=0.50 for pCR) with 95% confidence intervals.
• Findings were validated through sensitivity analyses restricted to multivariable-adjusted estimates.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Substantial heterogeneity and inconsistent NLR cutoffs across studies are noted in the conclusion.
• The dataset is a 27.2 KB document, indicating a limited scope focused on summary statistics rather than raw patient data.

Provenance

Source

Ziqian Zhao via figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, EMBASE, Web of Science, and the Cochrane Library.

Time Range

Studies published up to April 2026.

Freshness

Last updated 2026-05-29 04:52:35; freshness should be verified.